Organisation paid for research Program year 2024 Source: CMS Open Payments

Juno Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$358,030

772 payments

Through program year 2024, Juno Research, LLC is reported as receiving $358,030 in research payments, across 772 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$11,276	10
2023	Research	$39,238	46
2022	Research	$17,541	48
2021	Research	$177,858	510
2020	Research	$88,242	147
2019	Research	$23,876	11

Breakdown

Who paid Research payments · program years 2019–2024

Novo Nordisk AS $207,994 671 payments
Merck Sharp & Dohme Corporation $47,565 40 payments
CSL Behring $44,536 24 payments
Kowa Research Institute, Inc. $35,860 13 payments
Alnylam Pharmaceuticals Inc. $22,074 24 payments

Studies the money was for Research payments · program years 2019–2024

Nn1436-4477 $72,412 395 payments
A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease $44,536 24 payments
Nn9924-4635 $44,433 55 payments
Nn9535-4321 $39,717 86 payments
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age $30,271 6 payments
Nn9535-4506 $28,400 6 payments
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) $22,074 24 payments
Nn1436-4481 $20,482 122 payments
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V591 MV SARS-CoV-2, Live, Recombinant in Healthy Individuals 16 Years of Age or Older $15,500 6 payments
K-877-301 $12,418 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.